Lipid Lowering Treatment and Eligibility for PCSK9 Inhibition in Post-Myocardial Infarction Patients in Italy: Insights from Two Contemporary Nationwide Registries

• Main Authors: Furio Colivicchi (Author), Michele Massimo Gulizia (Author), Marcello Arca (Author), Pier Luigi Temporelli (Author), Lucio Gonzini (Author), Vanessa Venturelli (Author), Nuccia Morici (Author), Ciro Indolfi (Author), Domenico Gabrielli (Author), Leonardo De Luca (Author)
• Format: Book
• Published: Hindawi-Wiley, 2020-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Introduction. The current use of lipid lowering therapies and the eligibility for proprotein convertase subtilisin/kexin-9 (PCSK9) inhibitors of patients surviving a myocardial infarction (MI) is poorly known. Methods. Using the data from two contemporary, nationwide, prospective, real-world registr...